ProPhase Labs, Inc. Finance Lease, Right-of-Use Asset, Amortization
ProPhase Labs, Inc. (PRPH) reported Finance Lease, Right-of-Use Asset, Amortization of $317.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-19
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $317.00K, a 19.13% decline year-over-year.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $317.00K, a 19.13% decline year-over-year.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $317.00K, a 19.13% decline year-over-year.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $392.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $1.49M, a 10.10% increase from fiscal 2024.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $1.36M, a 78.42% increase from fiscal 2023.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $760.00K.
- ProPhase Labs, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 3 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 9 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $317.00K 10-Q · filed 2026-08-19 | $634.00K 10-Q · filed 2026-08-19 | $951.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.34M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2026-03-31 | $317.00K 10-Q/A · filed 2026-07-09 | $634.00K derived: sum of 2 quarters · filed 2026-07-09 | $1.03M derived: sum of 3 quarters · filed 2026-07-09 | $1.42M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $709.00K derived: sum of 2 quarters · filed 2026-06-01 | $1.10M derived: sum of 3 quarters · filed 2026-08-19 | $1.49M 10-K · filed 2026-06-01 | ||
| 2025-09-30 | $392.00K 10-Q · filed 2025-11-19 | $784.00K derived: sum of 2 quarters · filed 2026-08-19 | $1.18M 10-Q · filed 2025-11-19 | $1.57M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-06-30 | $392.00K 10-Q · filed 2026-08-19 | $784.00K 10-Q · filed 2026-08-19 | $1.18M derived: sum of 3 quarters · filed 2026-08-19 | $1.57M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-03-31 | $392.00K 10-Q/A · filed 2026-07-09 | $784.00K derived: sum of 2 quarters · filed 2026-07-09 | $1.18M derived: sum of 3 quarters · filed 2026-07-09 | $1.57M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2024-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $784.00K derived: sum of 2 quarters · filed 2026-06-01 | $1.18M derived: sum of 3 quarters · filed 2026-06-01 | $1.36M 10-K · filed 2026-06-01 | ||
| 2024-09-30 | $392.00K 10-Q · filed 2025-11-19 | $1.17M 10-Q · filed 2024-11-13 | $784.00K derived: sum of 2 quarters · filed 2025-11-19 | $964.00K 10-Q · filed 2025-11-19 | $1.74M 10-Q · filed 2024-11-13 | $1.36M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $392.00K 10-Q · filed 2025-08-13 | $572.00K 10-Q · filed 2025-08-13 | $964.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.28M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $180.00K 10-Q · filed 2025-05-20 | $572.00K derived: sum of 2 quarters · filed 2025-05-20 | $890.00K derived: sum of 3 quarters · filed 2025-05-20 | $940.00K derived: sum of 4 quarters · filed 2025-05-20 | ||
| 2023-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $710.00K derived: sum of 2 quarters · filed 2025-04-01 | $760.00K derived: sum of 3 quarters · filed 2025-04-01 | $760.00K 10-K · filed 2025-04-01 | ||
| 2023-09-30 | $318.00K 10-Q · filed 2024-11-13 | $368.00K derived: sum of 2 quarters · filed 2024-11-13 | $368.00K 10-Q · filed 2024-11-13 | $368.00K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $50.00K 10-Q · filed 2024-08-14 | $50.00K 10-Q · filed 2024-08-14 | $50.00K derived: sum of 3 quarters · filed 2024-08-14 | $50.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-05-10 | $0.00 derived: sum of 3 quarters · filed 2024-05-10 | $0.00 derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |